Study S002106

Efficacy and Safety of Cagrilintide for Weight Management in Participants With Overweight or Obesity and Type 2 Diabetes

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07220759
Acronym: RENEW 2
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: QUADRUPLE
Status: ACTIVE_NOT_RECRUITING
Enrollment: 330
Start: 2025-11-05
Primary completion: 2027-05-12
Lead sponsor: Novo Nordisk A/S
Conditions: Overweight; Obesity; Type 2 Diabetes
Interventions: DRUG:Cagrilintide; DRUG:Placebo (matched to Cagrilintide)
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1314-9328; OTHER:2024-519531-41

Registered primary outcomes

Relative change in body weight [From baseline (week 0) to end of treatment (week 64)]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.